BUY Akums Drugs and Pharmaceuticals — Anand James, 22 Sept 2026

byAnand James, Geojit InvestmentsHorizon: NA (inferred Swing (≤2wk))22 Sept 2026via Business Standard Markets

Entry₹821Stated

Target₹860

Stop loss₹803-2.19% risk

CMP₹823.36h ago

Active+0.28%+4.46%upside left 13d left

Follow Anand James for new callsGet alerts Watch AKUMS for new buy/sell callsGet alerts See 1 other Swing call on AKUMS See 257 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 23 Sept, 10:21 pm IST

6 supporting1 neutral1 opposing

Supports the BUY call (6)

Akums Drugs Q1FY27 net profit surges 56%; concall flags API turnaround

NewsGoogle News·22 Sept · yesterday

Akums Announces DCGI-Approved Triple Therapy for H. pylori Infection

NewsGoogle News·21 Sept · 2d ago

Akums FY26 revenue rises 5.9% to ₹43,590.17 Mn

NewsGoogle News·20 Sept · 3d ago

Akums Share Price today near 52-week high on 2.72% rise

NewsGoogle News·18 Sept · 5d ago

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·15 Sept · 1w ago

Neutral / worth noting (1)

Akums Drugs to Host Analyst and Investor Meeting on September 22

NewsGoogle News·16 Sept · 1w ago

Weighs against the BUY call (1)

MACD below its signal line — bearish momentum

Technicals · macd·23 Sept · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

BUY Akums Drugs and Pharmaceuticals — Anand James, Geojit Investments

AI Assessment